$14.50 Million in Sales Expected for Adaptimmune Therapeutics PLC – (ADAP) This Quarter

Analysts expect Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) to announce sales of $14.50 million for the current quarter, according to Zacks. Two analysts have made estimates for Adaptimmune Therapeutics’ earnings, with the highest sales estimate coming in at $20.00 million and the lowest estimate coming in at $9.00 million. Adaptimmune Therapeutics posted sales of $4.27 million during the same quarter last year, which suggests a positive year over year growth rate of 239.6%. The business is scheduled to issue its next quarterly earnings results on Thursday, March 21st.

According to Zacks, analysts expect that Adaptimmune Therapeutics will report full-year sales of $66.26 million for the current financial year, with estimates ranging from $58.03 million to $78.00 million. For the next fiscal year, analysts anticipate that the company will post sales of $27.67 million, with estimates ranging from $24.00 million to $35.00 million. Zacks’ sales calculations are an average based on a survey of analysts that follow Adaptimmune Therapeutics.

Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported $0.06 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.03) by $0.09. Adaptimmune Therapeutics had a negative net margin of 139.57% and a negative return on equity of 41.63%. The business had revenue of $40.79 million for the quarter, compared to analysts’ expectations of $29.41 million.

ADAP has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of Adaptimmune Therapeutics from a “hold” rating to a “buy” rating and set a $7.75 price target on the stock in a research note on Wednesday, October 24th. ValuEngine cut shares of Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Monday, October 22nd. Raymond James lowered their price objective on shares of Adaptimmune Therapeutics from $20.00 to $16.00 and set a “buy” rating on the stock in a research note on Monday, October 22nd. BidaskClub raised shares of Adaptimmune Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, September 29th. Finally, Guggenheim assumed coverage on shares of Adaptimmune Therapeutics in a research note on Monday, September 17th. They issued a “buy” rating on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $15.44.

Shares of NASDAQ:ADAP traded down $0.07 on Friday, reaching $5.43. 618,043 shares of the company were exchanged, compared to its average volume of 523,253. Adaptimmune Therapeutics has a 1-year low of $5.20 and a 1-year high of $14.63. The stock has a market cap of $566.50 million, a PE ratio of -6.79 and a beta of 2.02.

In other Adaptimmune Therapeutics news, Director Ali Behbahani acquired 12,000,000 shares of the stock in a transaction that occurred on Friday, September 7th. The shares were purchased at an average cost of $1.67 per share, with a total value of $20,040,000.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Gwendolyn Knowlt Binder-Scholl sold 25,000 shares of the stock in a transaction dated Wednesday, August 29th. The shares were sold at an average price of $10.25, for a total transaction of $256,250.00. The disclosure for this sale can be found here. 26.47% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Stanley Laman Group Ltd. acquired a new stake in Adaptimmune Therapeutics in the 3rd quarter valued at about $7,665,000. Bellevue Group AG purchased a new position in Adaptimmune Therapeutics in the 2nd quarter valued at about $711,000. BlackRock Inc. lifted its holdings in Adaptimmune Therapeutics by 2.5% in the 1st quarter. BlackRock Inc. now owns 806,952 shares of the biotechnology company’s stock valued at $9,062,000 after purchasing an additional 19,765 shares in the last quarter. Creative Planning lifted its holdings in Adaptimmune Therapeutics by 17.5% in the 3rd quarter. Creative Planning now owns 120,900 shares of the biotechnology company’s stock valued at $1,639,000 after purchasing an additional 18,000 shares in the last quarter. Finally, Baillie Gifford & Co. lifted its holdings in Adaptimmune Therapeutics by 18.2% in the 2nd quarter. Baillie Gifford & Co. now owns 3,033,261 shares of the biotechnology company’s stock valued at $36,005,000 after purchasing an additional 467,852 shares in the last quarter. 60.13% of the stock is currently owned by hedge funds and other institutional investors.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.

Read More: The Structure of a Futures Contract

Get a free copy of the Zacks research report on Adaptimmune Therapeutics (ADAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply